Introduction to Pediatric Stroke Risk Phenotypes

Children with sickle cell disease (SCD) face a significantly elevated risk of developing severe cerebral vasculopathies. Understanding the specific pediatric stroke risk phenotypes is essential for clinicians who manage these complex cases. Recent institutional research has focused on the differences between patients with homozygous SCD (HbSS) alone and those who also present with concurrent moyamoya arteriopathy (MMA). This distinction is critical because it directly influences the timing of vascular events and the potential need for surgical intervention.

Timing and Presentation of Stroke

The presence of moyamoya arteriopathy creates a more aggressive clinical trajectory in pediatric SCD patients. Research indicates that children with both SCD and MMA often experience earlier strokes compared to those with SCD alone. Consequently, these patients may require more intensive neuroimaging surveillance and early referral to neurosurgical teams. Furthermore, the phenotype of the stroke—whether ischemic or involving specific collateral vessel patterns—differs based on the underlying vascular pathology. Therefore, early detection of MMA through transcranial Doppler or MRI is a clinical priority.

Managing Complex Cerebrovascular Profiles

Traditional medical management for SCD, such as chronic transfusion therapy, provides substantial protection. However, it may not be sufficient for those displaying aggressive pediatric stroke risk phenotypes linked to MMA. In these instances, surgical revascularization, such as pial synangiosis, often becomes a necessary consideration. This surgical approach aims to augment cerebral blood flow and provide a stable secondary blood supply. Clinicians must weigh the risks of perioperative complications against the high probability of recurrent infarction in untreated moyamoya syndrome.

Clinical Implications for Pediatric Practice

Monitoring for vascular progression should begin early in childhood. Because the risk of stroke is highest in the first decade of life, proactive screening remains the gold standard. In addition, the identification of silent infarcts on MRI should trigger immediate discussion regarding escalated therapy. Ultimately, a multidisciplinary team including hematologists, neurologists, and surgeons is necessary to navigate the complexities of these phenotypes and optimize long-term neurological outcomes.

FAQ

How does moyamoya arteriopathy affect stroke timing in children with SCD?

Moyamoya arteriopathy typically accelerates the progression of vasculopathy, leading to an earlier onset of symptomatic strokes compared to patients with sickle cell disease alone.

What are the primary pediatric stroke risk phenotypes in this population?

Phenotypes are generally divided into those with simple sickle cell-related large vessel stenosis and those with complex moyamoya-type collateralization, with the latter requiring more aggressive surgical consideration.

Can surgical revascularization prevent recurrent strokes?

Yes, surgical revascularization has been shown to reduce the rate of recurrent cerebrovascular events in children with SCD and moyamoya syndrome compared to medical management alone.

Disclaimer: This content is for informational and educational purposes only. It is not intended as medical advice or a substitute for professional clinical judgment. Refer to the latest local and national guidelines for clinical practice.

References

Papadakis JE et al. Understanding stroke risk phenotypes in pediatric patients with sickle cell disease and concurrent moyamoya arteriopathy: insights from 61 cases at a single institution. J Neurosurg Pediatr. 2026 Mar 13. doi: 10.3171/2025.11.PEDS25151. PMID: 41825074.

Guidelines on sickle cell disease: secondary stroke prevention in children and adolescents. Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular. Rev Bras Hematol Hemoter. 2022.

Alamri M et al. Cerebrovascular Event and Stroke Rates in Pediatric Patients with Sickle Cell Disease and Moyamoya Syndrome: a Systematic Review. Pediatric Stroke Journal. 2024.